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Abstract 
Background:  The pathogenic potential of the parasite Blastocystis hominis is often considered controversial.  
However, it is now gaining acceptance as a human intestinal parasitic agent showing different clinical symptoms. 
Objective: To determine the prevalence and related clinical manifestation of B. hominis infection in patients referred 
for bacteriological stool culture at the Ethiopian Health & Nutrition Research Institute (EHNRI). 
Methods: A total of 152 patients referred for bacteriological stool culture to the bacteriology and parasitology labs at 
EHNRI, were examined for possible infection with B. hominis. A single stool sample from each individual was 
collected and processed for isolation of bacteria by using a standard culture method for enteric bacteria, while direct 
and formol-ether concentration methods were used for the detection of ova and parasites; and the Modified Ziehl 
Neelsen method was applied for Cryptosporidium parvum and Isospora belli and water-ether sedimentation with 
Uvitex-2B staining method was used for detecting intestinal microsporidia. Clinical information was recorded during 
stool sample collection.  
Results: One Salmonella spp., two Shigella spp. and one case of Escherichia coli were isolated.  Blastocystis hominis 
was detected in 71(46.7%) of the 152 patients examined and 51/71(71.8%) of the patients were found to have been 
infected with B. hominis alone. Well known opportunistic intestinal parasites - Cryptosporidium parvum 11(7.2%), 
Isospora belli 13 (8.6%) and Enterocytozoon bieneusi 2 (1.3 %) - were also recorded. Among the helminths, 
Strongyloides stercoralis 5 (3.3 %) was identified to be the most prevalent.  The most common clinical symptoms 
significantly associated with B. hominis were distension, flatulence and anorexia (P<0.05).  Among the positive cases, 
four staff members (three males aged 38, 40 and 45 years old and one female aged 42 years old) who were infected 
with B. hominis alone were treated with metronidazole 250 mg, 2 tablets three times a day for 10 days, and responded 
favourably and all clinical symptoms resolved.    
Conclusions: This information is expected to strengthen the newly emerging perception on the pathogenic potential of 
B. hominis infection. It will also create an awareness of laboratory technicians and physicians for proper diagnosis and 
management of the disease.  From this and other related studies conducted elsewhere, it could be concluded that 
treating B. hominis infections where defined symptoms are presented with large numbers of parasites in the stool and 
in the absence of other cases of the disease is recommendable.  [Ethiop.J.Health Dev.  2006;21(1):61-67] 
 
Introduction 
Until recently, Blastocystis hominis has been described as 
a non-pathogenic human intestinal protozoan parasite 
with a worldwide distribution. However, controversy 
surrounds   its pathogenic potential (1,2).   Different 
surveys have pointed out that the infection rate can vary 
from 1.6% in industrialised countries to more than 50% 
in developing countries (2,3).  Blastocystis hominis 
infection is more common in developing countries in the 
tropical and subtropical regions (4,5). 
 
B. hominis, formerly considered as a yeast, has recently 
been reported to have protozoan characteristics 
supporting its classification as an intestinal protozoan 
parasite (6,7,8). Different diarrhoeal illnesses and other 
clinical symptoms have been attributed to B. hominis 
infection in subtropical countries (1,2,4,5).  Some 
investigators have reported the problem of B. hominis 
infection in symptomatic and asymtomatic cases (9,10). 
 
The problem of B. hominis infection in AIDS patients has 
been reported (11, 12, 13, 14, 15).  Garavelli et.al., (13) 
indicated that patients with full-blown AIDS and who 
test positive for Blastocystis hominis presented with 
diarrhoea, nausea, flatulence, tenesmus, itching, 
abdominal pain and peripheral blood eosinophilia. 
However, unlike other newly emerging opportunistic 
intestinal parasites (such as Cryptosporidium parvum, 
Isospora belli, Enterocytozoon bieneusi and 
Encephalitozoon intestinalis), B. hominis has not been 
studied well and recognised as an important opportunistic 
pathogen in immunocompromised and HIV/AIDS 
patients. The prevalence of this parasite in developing 
countries is very high, yet there is no adequate 
information about its pathogenic potential. According to 
previous studies done in Ethiopia, Fisseha et.al (16), for 
example, identified a single case of B. hominis out of 143 
HIV/AIDS patients and Hailemariam et.al. (17) detected 
5 cases among 234 HIV infected individuals. In addition, 
B. hominis parasite was detected from baboons and 
vervet monkeys from the Rift Valley area of Ethiopia, 
depicting its zoonotic nature (18). The zoonotic potential 
of B hominis. infection and speculation on strain 
variation that resulted in differences of pathogencity of 
the parasites has been demonstrated by different 
investigators (19, 20). 
 
Different diagnostic methods are used for the detection of 
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Blastocystis hominis infections, such as culturing and 
staining of the parasites from faecal samples. In addition, 
the diagnosis of B. hominis (abbreviated for Blastocystis 
throughout the rest of the paper) infection involves iodine 
stained wet mount direct microscopy for the 
differentiation of the internal structures.  Examining the 
in vitro culture of the parasite is another well-established 
method (21). However, in most health institutions, 
especially in developing countries where other well-
recognised intestinal parasites are rampant diagnosis, the 
reporting and treatment of Blastocystis hominis infections 
have been overlooked by the laboratory technicians and 
physicians (22). Most of the researchers have indicated 
the following two criteria for considering Blastocystis 
hominis as a pathogen: (i) when present in large numbers 
(greater than 5 per high power field) and (ii) when 
diagnosed in the absence of other potential pathogens (2, 
9,23). 
 
Morphological heterogeneity is observed in Blastocystis 
hominis parasites, which have significance for the 
diagnosis of the infection.  Among these, the amoeboid 
form is small in diameter (2.6-7.8μm), irregular in shape 
and often has extended pseudopodia and possesses one or 
two nuclei located at the center of the cell (2,8). This 
form is commonly detected in symptomatic patients with 
diarrhoea stool samples (2, 24).  The vacuolated form 
measures 5-30µm, and is predominant in faecal 
specimens. This form has been considered to be the 
typical cell form and is generally used for the diagnosis 
of Blastocystis hominis. The granular form of Blastocytis 
hominis has an ultrastructure similar to that of the 
vacuolar form, apart from having morphologically and 
cytochemically different central vacuoles  (1,2,6). 
 
This study is aimed at determining the prevalence of 
Blastocystis hominis and to evaluate its potential clinical 
significance in the absence of other intestinal pathogens 
in patients referred for bacteriological stool culture. 
 
Methods 
Study subjects and sample collection:  A single fresh 
stool specimen was collected from each of the 152 
patients who were referred to the bacteriology laboratory 
at the EHNRI for bacteriological stool culture 
examination from March 2003 to May 2004.  Clinical 
information such as abdominal pain, nausea, vomiting, 
distension, anorexia, flatulence, bowel movement/day, 
type of diarrhoea, appearance of stool was collected 
during sample collection. The population included were 
children, adolescent, adults and the elderly of both sexes.  
Fresh stool samples were collected in a sterile Petri dish 
and transported immediately to the bacteriology 
laboratory for processing. From there, the remaining 
portion of stool samples was taken to the parasitology 
laboratory for further analysis for different intestinal 
parasites. 
 
Parasitological  methods:    Fresh   stool   samples   were 
processed by direct wet mount and formol-ether 
concentration method for the detection of ova and 
parasites. The slides were observed under light 
microscope with 100X and 400X magnifications by 
adding lugol’s iodine for the detection of protozoan 
parasites. Blastocystis hominis parasite in faecal 
specimens varies in shape and diameter (3-20μm). In wet 
mounts, all appear as refractile organisms with or without 
a single vacuole, and with four to six ‘dots’ clustered 
around the rim or within the body of the organism. The 
number of Blastocystis hominis parasites >5 parasites per 
high power field (7,9) was recorded.  
 
Detection of coccidian intestinal parasites using the 
Modified-Ziehl Neelsen method:  Oocysts of the 
parasites were sought by direct smear as well as smears 
from the sediment by using the formol-ether 
concentration method.   The smears were air dried and 
then fixed in methanol for 5 minutes followed by staining 
with carbol fuschin for 30 minutes. After washing in tap 
water, the slides were decolourised with 1% acid-alcohol 
for three minutes.  After being washed in tap water, the 
slides were counterstained with 0.5% methylene blue for 
one minute.  Then the slides were observed under oil 
immersion using a light microscope. Oocysts usually 
appeared bright pink or dark-red against a blue 
background. The size of oocyst of Cryptosporidium 
parvum was 4-6 µm while oocyst of Isospora belli 
measures 10-19 µm by 20-30µm. Each slide was 
observed for 10 minutes to decide whether the slide is 
positive or negative. 
 
Detection of intestinal microsporidia:  Fresh stool 
samples were processed by a water-ether sedimentation 
method for staining by the Uvitex-2B method as 
described previously (25). Briefly, 8ml of distilled water 
was taken in a 15 ml conical test tube.  One gram of fresh 
stool is added and mixed thoroughly.  After sieving with 
gauze, 3ml of ether was added. The mixture was shaken 
for one minute and centrifuged at 2000g for 2 minutes.  
From the sediment, thin smears were prepared on 
microscope slides and allowed to air dry.  The slides 
were fixed in methanol for 5 minutes followed by 
staining with Uvitex-2B for ten minutes. After washing 
in PBS, the slides were counter-stained with 0.5% Evans 
blue (sigma) for 30 seconds. After washing in PBS, the 
slides were observed under the fluorescent microscope 
with a 50-w Mercury high-pressure lamp, excitation filter 
of 355-425 nm and suppression filter of 460 nm (Leitz 
Ploemopack Filter Block D, Germany) at the 
magnification of X1000 for the presence of spores of 
intestinal microsporidia.  Each slide was observed for 
about 10 minutes to decide whether it was positive or 
negative. 
 
Isolation of entropathogenic bacteria:  All fresh stool 
specimens were brought to bacteriology laboratory 
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immediately and tested for Salmonella spp., Shigella 
spp., Vibro cholerae and diarrheogenic Escherichia coli 
by using a standard culture method. Briefly, fresh stool 
samples were inoculated on to a MacConkey agar (MA), 
Salmonella-Shigella agar (SS), Thiosulfate Citrate Bile 
Sucrose agar (TCBS) and Butzer Campylobacter plates 
and incubated at 370C for 24 hours. The plates were read 
and identified by experienced technicians. Further 




Out of the 152 samples requested for bacteriological 
culture only 4 (2.6%) were found to be positive for 
bacteria: 1 Salmonella spp, 2 Shigella spp. and 1 case of 
Escherichia coli were isolated.  The same samples were 
analysed for different intestinal parasites. Among these, 
71/152 (46.7%) were found to be positive for Blastocystis 
hominis parasites. Infection with Blastocystis hominis 
was considered as positive only when the parasite count 
is greater than 5 per high power field of the light 
microscope. This is based on an established rating 
procedure in various studies conducted by different 
investigators elsewhere (7,9,23). Opportunistic intestinal 
parasites, Cryptosporidium parvum 11(7.2%), Isospora 
belli 13(8.6%) and Entero-cytozoon bieneusi 2 (1.3%) 
were detected.  Among the helminths, Strongyloides 
sterocoralis 5 (3.3%), Trichuris trichiura 4(2.6%), 
Ascaris lumbricoides and Schistosoma mansoni 1(0.7%) 
each and Hookworm spp. and Taenia spp. each 2 (1.3%) 
were recorded (Table 1). Pathogenic intestinal protozoan 
Entamoeba    histolytica/dispar   9(5.9%)   and   Giradia 
lamblia 6 (3.9%) were identified. Non-pathogenic 
intestinal protozoa were also observed.  Entamoeba coli 
15(9.9%), Endolimax nana 4 (2.6%), Iodoamoeba 
butschilli and Chilomastix mesnelli 1(0.9%) each, and 
Sarcocystis spp. 5 (3.3%) were identified. 
 
Out of 71 B. hominis infections, B. hominis alone was 
detected in 51/71 (71.8%) specimens and in 
20/71(28.2%) with other intestinal parasites.  Concurrent 
infections   with pathogenic and non-pathogenic 
intestinal parasites were also recorded (Table 2). Among 
the pathogenic, coccidian parasites Cryptosporidium 
parvum and Isospora belli 2 (4%) each were detected.  
Entamoeba coli 5 (10%), Endolimax nana 2(4%) and 
Iodoamoeba butchilli 1(2%) were among the non-
pathogens, and 2 (4%) of Strongylodes stercoralis and 
1(2%) of Trichuris trichuria were also concurrently 
detected. 
 
The major clinical manifestations noted with Blastocystis 
hominis alone were distension in 43 (84.3%), flatulence 
in 41 (80.4%) and anorexia in 43 (86%) and were 
significantly higher (P<0.05) in is group than in those 
with concurrent infection.  Abdominal pain with 
cramping and vomiting was also recorded.    In 31 
(60.8%) of the cases, bowel movement per day was 4 
times and in 28 (54.8%) the nature of diarrhoea was 
intermittent (Table 3). 
 
Table 1: Prevalence of intestinal parasites and bacteria 
detected in the stool samples referred for bacteriological 
culture 
Parasite identified No. positive (%) (N=152) 
Protozoa  
Blastocystis hominis 71 (46.7) 
Isospora belli 13 (8.6) 
Cryptosporidium parvum 11 (7.2) 




Giardia lamblia 6 (3.9) 
Entamoeba coli 15 (9.9) 
Endolimax nana 5 (3.3) 
Chilomatix mesnelli 1 (0.7) 
Entamoeba hartmanni 1 (0.7) 
Iodoamoeba butcheilli 1 (0.7) 
Sarcocystis spp. 5 (3.3) 
Helmiths  
Ascaris lumbricoides 1 (0.7) 
Trichuris trichiura 4 (2.6) 
Strongyloides stercoralis 5 (3.3) 
Hookworm spp. 2 (1.3) 
Schistosoma mansoni 1 (0.7) 
Taenia spp. 2 (1.3) 
Hymenolepis nana 1 (0.7) 
Bacteria  
Salmonella spp. 1 (0.7) 
Shigella spp. 2 (1.3) 
Escherichia coli 1 (0.7) 
 
 
Table 2: Concurrent infection with Blastocystis 
hominis with other protozoa (n=20) 
Parasites Identified No. positive (%) 
Cryptosporidium parvum 2 (2.8) 
Isospora belli 2 (2.8) 
Strongyloides stercoralis 2 (2.8) 
Entamoeba coli 5 (7.0) 
Entamoeba histolytica/dispar 2 (2.8) 
Endolimax nana 3 (4.2) 
Giardia lamblia 2 (2.8) 
Iodoameaba butchilli 1 (1.4) 
Trichuris trichuria 1 (1.4) 
 
The clinical features recorded in those Blastocystis 
hominis infections with other intestinal parasites were 
abdominal cramps, distension, anorexia and flatulence 
(Table 3) but with no significant differences among the 
groups (P>0.05).  The nature of diarrhoea in the majority 
of Blastocystis hominis with other parasites was 
intermittent in 12 (60.0%) and loose appearance in 17 
(85.0%) of the cases. 
 
The prevalence of intestinal parasites was higher in males 
than in females (Table 4), but with no significant 
difference between the sexes (P>0.05).  The prevalence 
of intestinal parasites with age dependence range cannot 
be analysed because the majority of the patients were 
aggregated in the age range of 20-40 years. 
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Table 3:  Clinical features of patients infected with Blastocytis hominis alone and Blastocystis hominis with 
other intestinal parasites 
Features Blastocystis alone 
(%) (n=51) 
Blastocystis with others 
(%) (n=20) 
P-value 
Abdominal pain 47 (92.2) 18 (90.0)  
Nausea 26 (51.0) 12 (60.0)  
Vomiting  9 (17.6)  3 (15.0)  
Distension 43 (84.3)* 15 (75.0) *P=0.008 
Anorexia 40 (78.4)* 14 (70.0) *P=0.046 
Flatulence 41 (80.4)* 15 (75.0) *P=0.013 
Fever 16 (31.4)  6 (30.0)  
Tensmus 20 (39.2)  8 (40.0)  
Bowel movement/ day:    
1X  1 (2.0)  0  
2X  6 (11.8)  2 (10.0)  
3X  7 (13.7)  1 (5.0)  
4X 31 (60.8) 15 (75.0)  
≥5X  6 (11.8)  2 (10.0)  
Type of diarrhoea    
Intermittent 28 (54.8) 12 (60.0)  
Chronic 12 (23.8)  8 (40.0)  
Acute 11 (21.6)  0  
Appearance    
Loose 42 (82.4) 17 (85.0)  
Formed  1 (2.0)  0  
Watery  8 (15.7)  3 (15.0)  
Bloody  0  0  
Mucoid  0  0  
* P<0.05 
 
Table 4:  prevalence of intestinal parasite from stool samples referred for stool culture by sex 
Parasite identified Male (%) (n=93) Female (%) (n=59) Total (%) (n=152) 
Protozoa    
Blastocystis hominis* 44 (47.3) 27 (45.8) 71 (46.7) 
Isospora belli  9 (9.7)  4 (6.8) 13 (8.6) 
Cryptosporidium parvum  5 (5.4)  6 (10.2) 11 (7.2) 
Enterocytozoon bieneusi  2 (2.2)  0 (0.0)  2 (1.3) 
Entamoeba histolytica/dispar  6 (6.5)  3 (5.1)  9 (5.9) 
Giardia lamblia  3 (3.2)  3 (5.1)  6 (3.9) 
Entamoeba coli  7 (7.5)  8 (13.6) 15 (9.9) 
Endolimax nana  3 (3.2)  3 (3.2)  6 (3.3) 
Chilomatix mesnelli  1 (1.1)  0 (0.0)  1 (0.7) 
Entamoeba hartmanni  0 (0.0)  1 (1.7)  1 (0.7) 
Iodoamoeba butcheilli  1 (1.1)  0 (0.0)  1 (0.7) 
Sarcocystis spp.  3 (3.2)  2 (3.4)  5 (3.3) 
Helmiths    
Strongyloides stercoralis  3 (3.2)  2 (3.4)  1 (0.7) 
Trichuris trichuria  3 (3.2)  1 (1.7)  4 (2.6) 
Ascaris lumbricoides  1 (1.1)  0 (0.0)  1 (0.7) 
Hookworm spp. 2 (2.2)  0 (0)  2 (1.3) 
Schistosoma mansoni 0 (0.0)  1 (1.7)  1 (0.7) 
Taenia spp. 2 (2.2)  0 (0.0)  2 (1.3) 
Hymenolepis nana 0 (0.0)  1 (1.7)  1 (0.7) 
Bacteria    
Salmonella spp. 0 (0.0)  1 (1.7)  1 (0.7) 
Shigella spp. 0 (0.0)  2 (3.4)  2 (1.3) 
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Discussion 
The question of whether Blastocystis hominis is 
pathogenic or a commensal parasite or perhaps is capable 
of being pathogenic in specific situations has remained 
controversial.  However, there have been many reports 
suggesting that B. hominis causes illness in some infected 
individuals (2,3,10,13,19). 
 
According to previous reports from Ethiopia, very few 
cases of human infection were identified among 
HIV/AIDS patients (16,17).  Even though the immune 
status of our study subjects was not known, 71/152 
(46.8%) of the examined individuals in this study were 
positive for B. hominis, and some of the cases 
concurrently occurred with other pathogenic and non-
pathogenic intestinal parasites.  A similar B. hominis 
infection rate was reported by the EHNRI Parasitology 
Laboratory, 96/135 (71.0%) (unpublished report, 2004) 
among referred patients.  In the present study, patients 
with B. hominis infection presented with abdominal pain 
with cramp, nausea, distension, anorexia, flatulence and   
minor symptoms such as fever, vomiting and tenesmus, 
which is in agreement with the findings of others 
elsewhere (1, 3, 9, 11, 12).  Clinical symptoms like 
distension, anorexia and flatulence were significantly 
higher (P<0.05) in patients with B. hominis infections 
alone; similar findings were noted by other investigators 
(1, 2, 3, 26).  In the majority of the patients, the nature of 
diarrhoea was intermittent with frequency of bowel 
movement which is 4 times a day.  The appearance of the 
stool in the majority of the individuals was loose, and in 
rare cases it was watery.  This is in agreement with the 
findings of others, who suggested that infection with B. 
hominis is non-specific and includes diarrhoea; 
sometimes profuse watery without blood or leukocytes, 
nausea, and abdominal pain (2, 26). 
 
Several case reports suggested that B. hominis could 
infect extraintestinal sites such as infection of synovial 
fluids which results in joint pain, swellings and arthritis 
(2,31,32).  In the present study, some non-specific 
symptoms such as gastroenteritis and inflammation of the 
extremities were noted in patients with B. hominis 
infections alone.  In addition, among the study subjects, 
the cases of four staff members aged 38, 40 and 45 years 
old, males and 42 years old, female who gave stool 
samples for bacterial culture was described.   Abdominal 
cramping, distension, and flatulence with intermittent 
type of diarrhoea were their main problem. Two of them 
had severe diarrhoea, i.e., bowel motion frequency was 
greater than 5 times per day. One had anorexia and 
tenesmus. Similar information was documented by 
Rolston et.al., (27) in individuals with B. hominis 
infection.  Stool culture for bacteria was negative in all of 
the four cases. Except B. hominis, no other pathogenic or 
non-pathogenic intestinal parasites were detected among 
the four cases.  Three of them had the parasite load 
greater than 5 per high power field.  In fact, their immune 
status is not known.  All of them were treated with 
metronidazole at the dose of 2x3 tablets of 250 mg for 10 
days. A week after treatment, they gave stool sample for 
check up and no B. hominis parasite was found in their 
stool. They responded favourably to treatment and all 
symptoms were resolved.   This observation has given 
additional supportive evidence to recognise that B. 
hominis is a potential pathogen of humans in the absence 
of other pathogenic organisms and when the parasite load 
is > 5 under high power field (7,9,23). The rest of the 
positive patients were treated in the respective health 
institutions that referred them for bacteriological stool 
culture to the Bacteriology Laboratory of EHNRI. 
 
Meanwhile, co-occurrence of B. hominis infection with 
other well known pathogenic organisms may confuse its 
pathogenic potential. The clinical symptoms observed 
may lead to focus on other widely recognised pathogenic 
ones than B. hominis infection (28,29). However, in this 
study, the number of co-infections with other pathogenic 
intestinal parasites is very low with no significant 
differences in clinical manifestations (P>0.05).  
Concurrent infection with non-pathogenic intestinal 
protozoan parasites such as Entamoeba coli, and others 
may have an indication of similar routes of transmission, 
mainly faecal-oral contamination of foods and drinking 
water (1,9). It has been suggested that B. hominis is 
associated with the development of diarrhoea in travellers 
(4,30).  However, some reports indicated that the 
frequency of concurrent infections with other intestinal 
pathogens has confused the spectrum of the disease in 
travellers returning from developing countries infected 
with different species of intestinal parasites (28, 29,30). 
 
The other interesting findings observed in this study were 
that the opportunistic intestinal parasites- 
Cryptosporidium parvum, Isospora belli and 
Enterocytozoon bieneusi - were identified in patients 
complaining of gastrointestinal problems and who were 
referred only for bacteriological stool culture but not for 
detection of ova and intestinal parasites including 
opportunistic ones. Thus, this finding creates an 
awareness to perform additional type of stool 
examination for intestinal parasites with emphasis on 
opportunistic intestinal parasites in patients complaining 
of abdominal problems and associated illnesses. 
 
Conclusion 
The finding of this study is expected to create awareness 
among laboratory technicians and physicians about the 
proper diagnosis and management of the disease.  From 
this and other related studies elsewhere, it could be 
concluded that treating B. hominis infections where 
defined symptoms are present with a large number of 
parasites in the stool and in the absence of other cases of 
the disease is recommendable.  This study provides 
further supportive evidence for the pathogenic potential 
of B. hominis infection and its possible role in causing 
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clinical symptoms in the absence of other intestinal 
pathogens and when the parasite load is high. In addition, 
in-depth and extensive clinico-epidemiological studies 
must be conducted in order to confirm its true status of 
pathogenicity both in immunocompetent, 
immunocompromised and HIV/AIDS patients.   
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